MDMA combined with psychotherapy reduces PTSD symptoms substantially in clinical trials, but not through the mechanism researchers initially expected. An analysis of 53 patients who received the treatment found that mystical experiences — the profound sense of unity and transcendence that drives outcomes with psilocybin and LSD — played at most a minor role.
What mattered more was simpler: positive mood during the sessions.
The findings, published in the Journal of Psychopharmacology, come from a secondary analysis of two phase 2 randomised trials. Researchers led by Tijmen Bostoen at Leiden University Medical Center measured mystical experiences after each drug session using a standard 30-item questionnaire, then looked at whether those scores predicted symptom reduction.
MDMA scored about 42% on the mystical scale
Thirty-nine participants received standard doses of MDMA across two therapy sessions. Fourteen received an active placebo designed to produce some noticeable physical effects without the core MDMA experience.
Mean mystical experience scores in the MDMA group reached 63.1 out of a possible 150 — about 42% of the maximum. The placebo group scored 24.7, or roughly 16%. The difference was statistically clear, but the absolute scores were moderate. For comparison, a 2022 systematic review found that high mystical experience scores with classic psychedelics strongly predicted better outcomes across disorders. MDMA appears to produce something qualitatively different.
Mediation analysis showed that the positive mood subscale — measuring feelings of joy, peace and harmony during the session — had a small but significant indirect effect on PTSD symptom reduction. The other mystical dimensions, including the sense of unity or transcendence, did not.
Why the mechanism matters
MDMA is chemically an entactogen, not a classic psychedelic. It increases serotonin, dopamine and oxytocin, which tends to produce emotional warmth, empathy and reduced fear rather than the perceptual distortions and ego dissolution of psilocybin or LSD.
The authors suggest MDMA might support trauma processing by creating a safe emotional state in which patients can revisit distressing memories without being overwhelmed. The drug appears to lower activity in the amygdala — the brain region that signals threat — while maintaining enough cognitive clarity for structured therapy work.
Classic psychedelics, by contrast, seem to work by disrupting entrenched patterns of thought through mystical experiences that reshape a person’s sense of self and meaning. The two pathways may both be useful, but they are not the same pathway.
What this study can’t tell you
This was a secondary analysis of existing trial data. The mystical experience questionnaire was not the primary outcome measure, and the trials were not designed to test this specific question. The sample size of 53 is small for a mediation analysis, which makes the statistical estimates less stable.
All participants had chronic PTSD and were receiving MDMA in a clinical trial with extensive therapy support. The findings do not apply to recreational use of MDMA, which carries risks including neurotoxicity, hyperthermia and dangerous drug interactions. MDMA is not currently approved for medical use outside of trials.
The study also could not determine whether positive mood during the session was a side effect, a necessary condition for the therapy to work, or something in between. It is possible that feeling safe and connected allowed patients to engage more deeply with the therapeutic process, rather than the mood itself causing the improvement.
The clinical picture so far
Earlier trials found that MDMA-assisted therapy led to clinically meaningful reductions in PTSD symptoms, with about half of treated patients no longer meeting diagnostic criteria for the disorder after treatment. A 2021 phase 3 trial in people with severe PTSD confirmed the effect size was large enough to be practically useful.
Regulators in the United States and Europe are currently reviewing the evidence for possible approval. If approved, MDMA-assisted therapy would be the first novel pharmacological treatment for PTSD in decades.
The current findings suggest therapists working with MDMA should not aim to induce mystical states the way they might with psilocybin. The goal is more modest: create the emotional conditions under which someone can do difficult memory work. That still requires intensive preparation, supervision during the session, and integration therapy afterward, but the sessions themselves may look more like emotionally supported exposure therapy than a journey into altered consciousness.
Sources
- Bostoen, T.P.L., Krediet, E., van Schagen, A.M., van der Wee, N.J.A., & Giltay, E.J. (2026). The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis. Journal of Psychopharmacology. https://doi.org/10.1177/02698811261464502
Published for general education. This article is not medical advice, diagnosis or treatment. If you are struggling, speak to a qualified professional.